Áp dụng máy ép tim tự động trong cấp cứu bệnh nhân ngừng tuần hoàn tại khoa cấp cứu-Bệnh viện Bạch Mai

Abstract

Objectives: Evaluation of the efficacy and safety of Dienogest in the treatment of andenomyosis.

Subjects and methods: The retrospective descriptive study combined with advanced research on 42 patients with the confirmed uterine disease with medical records kept at the Central Obstetrics Hospital during the period from January 2018. Dienogest's effectiveness was assessed by assessing pre-change - treatment of clinical symptoms, menstrual blood count, VAS pain score, uterine size, quality of life score, and patient satisfaction. Safety was assessed based on adverse effects, liver and kidney function, blood count index, and blood biochemistry. Data were collected and processed using SPSS 20.0 software.

Results: Efficiency: reduction of clinical symptoms (menorrhagia from 30/42 patients to 25/42 patients, dysmenorrhea reduced from 35.7% to 8%, pelvic pain reduced from 23.8% to 8 %, painful defecation decreased from 11.9% to 8%, intercourse pain decreased from 16.7% to 8%, the rate of heavy menorrhagia/ hypermenorrhea decreased clearly, VAS pain score improved well through study time (After 3 months: 64.3%, After 6 months: 76.2%, After 9 months: 90.9%, After 12 months: 92.0%, good quality of life score is 16.7%) Fairly 50%; 95.2% satisfied with the improvement in menstrual pain; 85.7% was satisfied with the improvement in menstrual blood volume and 64.3% was satisfied with the improvement in menstrual bleeding. Safety: The most common adverse effect is menorrhagia (78.6%), there is no statistically significant change in subclinical indicators, anemia status is improved well through study time.